119-HR-7895 Journalist Public Summary

Public Summary — PBM Kickback Prohibition Act (H.R. 7895)

Headline Summary: The bill would forbid PBMs from paying brokers, consultants, or advisors for referrals when an employer health plan is choosing a PBM—closing a pay‑to‑play loophole in plan selection. [1]U.S. Government Publishing Office — GovInfo: H.R. 7895 (IH) — PBM Kickback Proh…

What It Does: Amends ERISA to bar any direct or indirect compensation from a PBM to an intermediary (like a benefits broker or consultant) for steering an employer plan or insurer to that PBM. The ban would apply to plan years that begin after the law takes effect. In plain terms, it targets referral fees that can bias advice employers receive when they shop for a PBM. [1]U.S. Government Publishing Office — GovInfo: H.R. 7895 (IH) — PBM Kickback Proh…

Why It Matters: Employers often rely on outside brokers/consultants to run PBM bids; undisclosed PBM payments to those intermediaries can create conflicts that may raise plan and patient costs. Policymakers are already moving on transparency (the Labor Department has a proposed PBM fee‑disclosure rule), and this bill goes further by prohibiting the referral payments outright. [2]edworkforce.house.gov

• House action: The Education & Workforce Committee approved H.R. 7895 on May 21, 2026, by 34–0, sending it to the full House. [3]U.S. House Committee on Education & the Workforce — House Education & the Workf…
• Employer plans: The ERISA Industry Committee (ERIC) publicly supports the bill as a way to end broker/consultant conflicts. [4]The ERISA Industry Committee — ERIC coalition letter supporting H.R. 7895 (Apr.…
• Independent pharmacists: NCPA endorsed the bill on markup day, calling these payments an “indefensible, pay‑to‑play racket.” [5]National Community Pharmacists Association — NCPA press release backing H.R. 78…

Who’s For It: See supporters above.

• PBM industry: Trade group PCMA argues added federal rules are unnecessary and risk weakening a competitive market; it emphasizes that employers value flexibility and that PBMs deliver savings—signaling opposition to measures that restrict contracting practices. [6]Pharmaceutical Care Management Association — PCMA press release: comments urgin…

Who’s Against It: See main opponent view above.

What’s Next: After committee approval, the bill heads to the House floor; if it passes, it would then move to the Senate for consideration. News coverage and the committee’s official vote log reflect the 34–0 committee vote on May 21, 2026. [3]U.S. House Committee on Education & the Workforce — House Education & the Workf…